Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age ≥ 18 years, able and willing to give signed and informed consent.~2. Patient with histologically proven recurrent de novo GBM:~   1. After at least a first-line standard of care (maximal safe resection, if feasible, radiation with temozolomide \[TMZ\], then TMZ);~  2. Any recurrence;~  3. Bevacizumab-naïve.\*~3. Patient eligible for carboplatin-based chemotherapy.~4. Patient eligible for a surgical resection.~5. Maximal tumor diameter at inclusion (pre surgery) ≤ 70 mm in T1wMRI.~6. Patients should be stable, without evidence of a midline shift, significant peritumoral edema, or rapid progression of clinical symptoms.~7. Karnofsky performance status ≥ 70.~8. Patient receiving prednisone dose ≤ 40 mg (dexamethasone ≤ 6 mg) for at least 7 days.~Key Exclusion Criteria:~1. Multifocal tumor (unless all localized in a 70 mm diameter area).~2. Patients at risk of surgery site infection (2 or more previous craniotomies, neurosurgery within the last 3 months, poor skin condition, and/or previously infected surgical field).~3. Posterior fossa tumor.~4. Uncontrolled epilepsy.~5. Patients with evidence of uncontrolled intracranial pressure.~6. Patients with known intracranial aneurism or having presented intra-tumor spontaneous hemorrhage.~7. Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer, non resorbable dura substitute, or reservoirs.~8. Patients with medical need to continue antiplatelet therapy.~9. Patients with known or suspected active or chronic infections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SonoCloud-9 Ultrasound + Carboplatin (Type: EXPERIMENTAL): SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).